YL-15293

YL-15293 is an orally bioavailable small molecule inhibitor targeting the KRAS G12C mutation, which is a specific oncogenic substitution in the KRAS gene found in various solid tumors. By selectively inhibiting the mutant KRAS G12C protein, YL-15293 aims to block downstream signaling pathways involved in tumor cell proliferation and survival. The drug is being developed primarily for advanced solid tumors harboring the KRAS G12C mutation, including non-small cell lung cancer (NSCLC) and colorectal cancer. Clinical trials are ongoing to evaluate its safety, tolerability, pharmacokinetics (PK), and preliminary efficacy in these patient populations[1][2][3][4][7].